Angela Y. Wehr

Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model

P. Weiden, L. V. von Moltke, M. Hard, 2017, CNS Drugs.

Aripiprazole Lauroxil Dosing Regimens: Understanding Dosage Strengths and Injection Intervals

P. Weiden, Yangchun Du, R. Sommi, 2020, CNS Spectrums.

Pharmacokinetic Evaluation of a 1-Day Treatment Initiation Option for Starting Long-Acting Aripiprazole Lauroxil for Schizophrenia

P. Weiden, Yangchun Du, L. V. von Moltke, 2018, Journal of clinical psychopharmacology.

Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil

Yangchun Du, L. V. von Moltke, M. Hard, 2019, Therapeutic advances in psychopharmacology.

Size matters: the importance of particle size in a newly developed injectable formulation for the treatment of schizophrenia

P. Weiden, L. V. von Moltke, Jonathan M. Meyer, 2019, CNS Spectrums.

Population Pharmacokinetic Analysis and Model-Based Simulations of Aripiprazole for a 1-Day Initiation Regimen for the Long-Acting Antipsychotic Aripiprazole Lauroxil

L. V. von Moltke, M. Hard, B. Sadler, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Long-acting formulations delivering aripiprazole: beyond single-value characterizations of steady-state pharmacokinetics

P. Weiden, L. V. von Moltke, M. Hard, 2017, Neuropsychiatric disease and treatment.

Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study

Michael J. Palte, Mark D. Tawa, N. Penner, 2019, Advances in Therapy.

Pharmacokinetics, Safety, and Tolerability of a 2-Month Dose Interval Regimen of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil: Results From a 44-Week Phase I Study

P. Weiden, Yangchun Du, L. V. von Moltke, 2020, CNS Drugs.